Tang Capital Management’s Stoke Therapeutics STOK Stock Holding History

Tang Capital Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.82M	Sell	300,000 -200,000	-40%	-$6.42M	0.45%	32
2026 Q1	$16.3M	Hold	500,000	–	–	0.83%	25
2025 Q4	$15.9M	Hold	500,000	–	–	0.78%	28
2025 Q3	$11.8M	Hold	500,000	–	–	0.45%	54
2025 Q2	$5.67M	Hold	500,000	–	–	0.29%	77
2025 Q1	$3.33M	Buy	500,000 +200,000	+67%	+$1.86M	0.18%	95
2024 Q4	$3.31M	Buy	+300,000	New	+$3.69M	0.22%	88

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tang Capital Management's STOK Position: Q2 2026 in Review

Tang Capital Management reduced its Stoke Therapeutics (STOK) stake by 40% in Q2 2026, selling an estimated $6.42M and leaving 300,000 shares worth $9.82M. The position accounts for 0.45% of the portfolio, ranked #32.

Tang Capital Management first reported a position in STOK in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.3M in Q1 2026. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Tang Capital Management held 300,000 shares of Stoke Therapeutics worth $9.82M as of Q2 2026.
Tang Capital Management sold 200,000 Stoke Therapeutics shares in Q2 2026, an estimated $6.42M.
Stoke Therapeutics made up 0.45% of Tang Capital Management's portfolio in Q2 2026, its #32 holding.
Tang Capital Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 7 quarters since.
Tang Capital Management's Stoke Therapeutics position peaked at $16.3M in Q1 2026.
198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.